Innovative partner network to facilitate integration of digital patient engagement and data capture in clinical research programs
Exco InTouch, the leading provider of patient engagement and data capture solutions for clinical research and healthcare providers, will unveil the Exco Valued Partner Network at The Partnerships in Clinical Trials Congress taking place in Las Vegas between 30 March and 2 April 2014. The company, which already services all of the world’s top ten pharmaceutical companies (ranked by 2013 revenues), will now highlight the competitive advantages, benefits and unique factors that mark out its novel Exco Valued Partner Network. Exco InTouch, which will be exhibiting at stand 416, will also demonstrate its approach to BYOD (bring your own device) and more broadly to data capture and patient engagement services across clinical and late phase programs.
The Exco Valued Partner Network, has been created to enable Exco InTouch’s extensive pool of partners to benefit from collaborative activities and to experience the full range of services and capabilities offered first hand. Unique services, available to Exco InTouch partners, include the Exco Partner Cloud, a secure web portal that supports partner business development teams. The cloud enables partners to access tailored demonstrations, videos, case studies and co-branded materials, as well as providing information on their experience working together.
Other notable benefits of the network include innovation in the use of every day technologies, rapid access to patient centric solutions, a modular approach to system delivery, a BYOD cost saving model and enabling incorporation of ePRO capture into clinical studies. In addition, the network provides valuable partner program benefits that range across governance, with executive team leaders assigned to champion each individual partnership, preferred flexible pricing, master services agreements, operational, marketing and strategic business support.
Tim Davis, CEO and co-founder of Exco InTouch commented “We are delighted to have the opportunity to highlight the extensive benefits and advantages that our partners can enjoy when they join our Exco Valued Partner Network. We are committed to strong partnerships with clients, seeing this as mutually beneficial to all concerned. We are always on the look-out for ways to optimize the value added services that we provide to customers in the field of data capture and patient engagement. Our partnership programs form an essential and integral component to our strategy for continuing to achieve this important objective.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.